medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 4

<< Back Next >>

Ann Hepatol 2013; 12 (4)

Pegylated interferon-α2b and ribavirin decrease claudin-1 and E-cadherin expression in HepG2 and Huh-7.5 cells

Rendón-Huerta EP, Torres-Martínez A, Charles-Niño C, Rivas-Estilla AM, Paez A, Fortoul TI, Montaño LF

Language: English
References: 47
Page: 448-457
PDF size: 420.26 Kb.


ABSTRACT

Background. Hepatitis C virus (HCV) infection usually results in long-term viremia. Entry of HCV into the hepatocyte requires claudin-1, -6, -9 and occludin. The efficacy of Pegylated interferon-α (PEG-IFN) treatment against HCV infection increased when ribavirin (RBV) was added to the therapeutic scheme. Our aim was to investigate if PEG-IFN plus RBV regulate claudin expression. Material and methods. HepG2, Huh-7 and Huh-7.5 cells were treated with PEG-IFN-α2a or α2b and/or RBV at different times before obtaining the cytosolic, membrane and cytoskeletal fractions. Claudin-1, 3, 4, 6, and 9, E-cadherin and occludin expression was evaluated by Western blot analysis. Transepithelial electrical resistance (TER) was also determined. Results. Claudin-1, 3, 4, 6, E-cadherin and occludin are constitutively expressed mainly in HepG2 cell membrane. Claudin-1 and E-cadherin cell membrane expression diminished after exposure to PEGIFNα2b (50 ng) + RBV(50 µg); the maximal decrease was observed with 200 ng of PEG-IFNα2b + 200 µg of RBV. The effect was less intense with PEG-IFNα2a. The inhibition of claudin-1 and E-cadherin expression in Huh-7 and Huh-7.5 cells was only observed with 200 ng of PEG-IFNα2b + 200 µg of RBV. TER diminished marginally in the HCV containing hepatoma cells with 200 ng of PEG-IFNα2b + 200 µg of RBV. Claudin-1 mRNA expression level was not affected by the combined treatment. Conclusion. The increased therapeutic efficacy of the PEG-IFNα2b plus RBV treatment could be secondary to the inhibition of claudin-1 and E-cadherin cell membrane expression.


REFERENCES

  1. Lauer GM, Walker BD. Hepatitis C virus infection. New Engl J Med 2001; 345: 45-52.

  2. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36: S21-S29.

  3. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-6.

  4. Benedicto I, Molina-Jimenez F, Barreiro O, Maldonado-Rodríguez A, Prieto J, Moreno-Otero R, Aldabe R, et al. Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum. Hepatology 2008; 48: 1044-53.

  5. Morita K, Furuse M, Fujimoto K, Tsukita S. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci USA 1999; 96: 511-6.

  6. Dubuisson J, Helle F, Cocquerel L. Early steps of the hepatitis C virus life cycle. Cell Microbiol 2008; 10: 821-7.

  7. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T, et al. Claudin-1 is a hepatitis C virus receptor required for a late step in entry. Nature 2007; 446: 801-5.

  8. Zheng A, Yuan F, Li Y, Zhu F, Hou P, Li J, Song X, et al. Deng, Claudin-6 and claudin-9 function as additional coreceptor for hepatitis C virus. J Virol 2007; 81: 12465-71.

  9. Meertens L, Bertaux C, Cukierman L, Cormier E, Lavillette D, Cosset FL, Dragic T. The tight junction proteins claudin- 1, -6 and -9 are entry cofactors for the hepatitis C virus. J Virol 2008; 82: 3555-60.

  10. Meredith LW, Wilson GK, Fletcher NF, McKeating JA. Hepatitis C virus entry: beyond receptors. Rev Med Virol 2012; 22: 182-93.

  11. Guan M, Wang W, Liu X, Tong Y, Liu Y, Ren H, Zhu S, et al. Three different functional microdomains in the hepatitis C virus hypervariable region I (HVRI) mediate entry and immune evasion. J Biol Chem 2012 [Epub ahead of print].

  12. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3: 47-52.

  13. Lohmann V, Korner F, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-3.

  14. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002; 76: 13001-14.

  15. Mullin JM, Soler AP, Laughlin JV, Kampherstein JA, Russo LM, Saladik DT, George K, et al. Chronic exposure of LLCPK1 epithelia to the phorbol ester TPA produces polyp-like foci with leaky tight junctions and altered protein kinase C-alpha expression and localization. Exp Cell Res 1996; 227: 12-22.

  16. Harris HJ, Davis C, Mullins JG, Hu K, Goodall M, Farquhar MJ, Mee CJ, et al. Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem 2010; 285: 21092-102.

  17. Frese M, Schwarzle V, Barth K. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002; 35: 694-703.

  18. Kanto T, Hayashi N. Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptative immunity. Intern Med 2006; 45: 183-91.

  19. Tanabe Y, Sakamoto N, Enomoto N, Kurosaki M, Ueda E, Maekawa S, Yamashiro T, et al. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J Infect Dis 2004; 189: 1129-39.

  20. Poynard T, Leroy V, Cohard M. Meta-analysis of interferon randomized trial in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89.

  21. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-9.

  22. Bocci V. Metabolism of protein anticancer agents. Pharmacol Ther 1987; 34: 1-49.

  23. Glue P, Fang JWS, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, et al. Pegylated interferon-a2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Clin Pharmacol Ther 2000; 68: 556-67.

  24. Perry CM, Jarvis B. Peginterferon-alpha-2a (40 Kd): a review of its use in the management of chronic hepatitis C. Drugs 2001; 61: 2263-88.

  25. Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 610-22.

  26. Maynard M, Pradat P, Gagnieu MC, Souvignet C, Trepo C. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther 2008; 13: 607-11.

  27. Jain MK, Pasipanodya JG, Alder L, Lee WM, Gumbo T. Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. Antimicrob Agents Chemother 2012. Doi: 10.1128/AAC.02208-12.

  28. Jia D, Rahbar R, Fish EN. Interferon-inducible Stat2 activation of JUND and CLDN4: mediators of IFN responses. J Interferon Cytokine Res 2007; 27: 559-66.

  29. Fedwick JP, Lapointe TK, Meddings JB, Sherman PM, Buret AG. Helicobacter pylori activates myosin light-chain kinase to disrupt claudin-4 and claudin-5 and increase epithelial permeability. Infect Immun 2005; 73: 7844-52.

  30. Yang W, Qiu C, Biswas N, Jin J, Watkins SC, Montelaro RC, Coyne CB, et al. Correlation oft he tight junction-like distribution of claudin-1 to the cellular tropism of hepatitis C virus. J Biol Chem 2008; 283: 8643-53.

  31. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanism. J Immunol 2003; 171: 6164-72.

  32. Llovet JM, Chen Y, Wurmbach E, Roayale S, Fiel MI, Schwartz M, Thung SN, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131: 1758-67.

  33. Kim NG, Koh E, Chen X, Gumbiner BM. E-cadherin mediates contact inhibition of proliferation through Hippo signaling- pathway components. Proc Natl Acad Sci USA 2011; 108: 11930-5.

  34. Mee CJ, Harris HJ, Farquhar MJ, Wilson G, Reynolds G, Davis C, van Ijzendoorn SC, et al. Polarization restricts hepattis C virus entry into HepG2 hepatoma cells. J Virol 2009; 83: 6211-21.

  35. Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Trembaly MJ, Gray-Owen SD, Arsenaults AL, et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PloS Pathogen 2010; 8: e1000852.

  36. Wei X, Jia ZS, Lian JQ, Zhang Y, Li J, Ma L, Ye L, et al. Inhibition of hepatitis C virus infection by interferon-gamma through downregulating claudin-1. J Interferon Cytokine Res 2009; 29: 171-8.

  37. Kawaguchi H, Akazawa Y, Watanabe Y, Takakura Y. Permeability modulation of human intestinal Caco-2 cell monolayers by interferons. Eur J Pharm Biopharm 2005; 59: 45-50.

  38. Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. Ribavirin suppresses elF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA 2004; 101: 18105-10.

  39. George A, Panda S, Kudmulwar D, Chhatbar SP, Nayak SC, Krishnan HH. Hepatitis C virus NS5A binds to the mRNA cap-binding eukaryotic translation initiation 4F (eIF4E) complex and up-regulates host translation initiation machinery through eIF4E-binding protein 1 inactivation. J Biol Chem 2012; 287: 5042-58.

  40. Foster GR. Pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004; 20: 825-30.

  41. Grace MJ, Cutler DL, Bordens RW. Pegylated IFNs for chronic hepatitis C. an update. Expert Opin Drug Deliv 2005; 2: 219-26.

  42. Dhalluin C, Ross A, Leuthold LA, Foser S, Gsell B, Müller F, Senn H. Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers. Bioconjug Chem 2005; 16: 504-17.

  43. Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H. Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and ist individual position isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem 2005; 16: 518-27.

  44. Boulestin A, Kamar N, Sandres-Saune K, Alric L, Vinel JP, Rostaing L, Izopet J. Pegylation of IFN-alpha and antiviral activity. J Interferon Cytokine Res 2006; 26: 849-53.

  45. Grace MJ, Cutler D. Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway. Antivir Chem Chemother 2004; 15: 287-97.

  46. Murao K, Imachi H, Yu X, Cao WM, Nishiuchi T, Chen K, Li J, et al. Interferon alpha decreases expression of human scavenger receptor class B1, a possible HCV receptor in hepatocytes. Gut 2008; 57: 664-71.

  47. Sarasin-Filipowicz M, Oakeley EJ, Duong FHT, Christen V, Terracciano L, Filipowicz W, Heim MH. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105: 7034-9.




2020     |     www.medigraphic.com